{"entity":{"id":"fabrice-andre","kind":"person","name":"Fabrice André","aka":[],"tldr":"Breast cancer geneticist who led SOLAR-1 and the SAFIR precision-medicine trials; ESMO President 2025-2026.","summary":"Fabrice André is Director of Research at Gustave Roussy and Professor of Medical Oncology at Paris-Saclay, and served as President of the European Society for Medical Oncology (ESMO) for 2025-2026. His specialisms are breast cancer, precision oncology and genomics-driven trials, using comprehensive genomic profiling. He leads the breast cancer genomics programme at Gustave Roussy and was principal investigator of SOLAR-1, the trial of alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer reported in the New England Journal of Medicine. He also led the SAFIR01 and SAFIR02 genomics-guided trials, with the Nature paper on SAFIR02-BREAST testing genomics to select treatment for metastatic breast cancer. His Gustave Roussy profile and PubMed listing are linked.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Fabrice_Andr%C3%A9","links":[{"label":"Gustave Roussy","url":"https://www.gustaveroussy.fr/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Andre%20F%5BAuthor%5D%20breast%20alpelisib"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["cgp"],"targets":["pik3ca"],"drugs":["alpelisib"],"companies":[],"institutions":["gustave-roussy","esmo"],"pathways":[],"terms":[],"trials":["solar-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Research, Gustave Roussy; Professor of Medical Oncology, Paris-Saclay","institutionId":"gustave-roussy","specialisms":["Breast cancer","Precision oncology","Genomics-driven trials","ESMO leadership"],"profiles":[{"label":"Gustave Roussy","url":"https://www.gustaveroussy.fr/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Andre%20F%5BAuthor%5D%20breast%20alpelisib"}],"papers":[{"title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1813904"},{"title":"Genomics to select treatment for patients with metastatic breast cancer (SAFIR02-BREAST)","journal":"Nature","year":2022,"doi":"10.1038/s41586-022-05068-3"}]},"route":"/people/fabrice-andre/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"}],"target":[{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/"}],"drug":[{"id":"alpelisib","kind":"drug","name":"Alpelisib","route":"/drugs/alpelisib/"}],"institution":[{"id":"esmo","kind":"institution","name":"European Society for Medical Oncology (ESMO)","route":"/institutions/esmo/"},{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/"}],"trial":[{"id":"solar-1","kind":"trial","name":"SOLAR-1","route":"/trials/solar-1/"}],"paper":[{"id":"paper-bertucci-metastatic-breast-genomics-nature-2019","kind":"paper","name":"Genomic characterization of metastatic breast cancers","route":"/key-papers/paper-bertucci-metastatic-breast-genomics-nature-2019/"},{"id":"paper-park-tils-untreated-early-tnbc-ann-oncol-2019","kind":"paper","name":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy","route":"/key-papers/paper-park-tils-untreated-early-tnbc-ann-oncol-2019/"}]}}